BTSG · NASDAQ · STOCK
BrightSpring Health Services, Inc. Common Stock (BTSG) Analysis
$63.77
52W $27.89 – $73.75
60/100
$12.51B
44.6
1.88
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is BTSG Bullish or Bearish?
Bullish.
Innellis AI committee rates BrightSpring Health Services, Inc. Common Stock (BTSG) Buy with a composite score of 60/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +15.35 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -4.65 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.50 across 6 articles, 14d). Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 19.0% shows genuine earnings power backing the valuation — Value
- EPS growing 440.8% YoY — Growth
- MACD histogram positive -- bullish momentum — Technical
- News sentiment is positive (+0.50 across 6 articles, 14d) — News
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- RSI at 78 is in overbought territory — Technical
- Bollinger bandwidth of 20.9% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
60/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 34%
of 192 Healthcare peers
Value Analyst
neutral
57
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 19.0% shows genuine earnings power backing the valuation
− P/E of 34.5 is moderate-to-rich
Growth Analyst
bullish
62
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 440.8% YoY
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− RSI at 78 is in overbought territory
Risk Analyst
neutral
52
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
− Bollinger bandwidth of 20.9% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
74
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.50 across 6 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 59.6 to 59.6.
- New bearish signals: 2 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Risk Analyst: +1 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
78.3
Overbought
MACD Histogram
1.002
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Lh Ll
Support
$37.24
Resistance
$73.36
Bollinger %B
0.90
Inside Bands
Price vs Moving Averages
EMA 9
$61.57
Above
EMA 21
$60.09
Above
EMA 50
$60.39
Above
EMA 200
$53.38
Above
Fundamental Analysis
Valuation
41
Growth
74
Profitability
23
Financial Health
66
Cash Flow
70
Valuation
P/E Ratio
44.6×
P/B Ratio
6.41×
PEG Ratio
0.13
Dividend Yield
0.00%
52W High
$73.75
52W Low
$27.89
Quality & Growth
ROE
1016.9%
ROA
297.3%
Gross Margin
1238.2%
Operating Margin
332.7%
Revenue Growth YoY
—
Debt / Equity
1.17
AI Fundamental Assessment
P/E ratio of 44.6 (rich relative to a 15-40x range); Price-to-book of 6.4x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 10.2%; Return on assets of 3.0%; Net margin of 2.0%; Gross margin of 12.4%; Current ratio of 1.59 (healthy short-term liquidity); Debt-to-equity of 1.17; Free cash flow per share is positive (1.95); Most recent quarter beat estimates by 11.2%; 2 consecutive earnings beats; EPS growth decelerating (+18.2% -> +15.4% QoQ); Analyst estimates rising over recent quarters
Get the Full BTSG Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →